I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway, which is to be found here - https://surreyccg.res-systems.net/PADFormularyV1Admin/Profile/Detail/7986
The Surrey & North West Sussex Area Prescribing Committee recommends the use of vedolizumab subcutaneous injection or vedolizumab intravenous infusion. Clinicians & patients will be able to choose the most appropriate product for them at the point of prescribing.
Please note: Dose escalation with vedolizumab is not commissioned for either presentation, by the APC collaborative organisations.
The PCN supports the use of Vedolizumab in the treatment of Crohn's Disease after prior therapy in line with NICE TA352. Vedolizumab will be given a RED status on the traffic light system
NICE TA342 - Vedolizumab for the treatment of Ulcerative Colitis was published by NICE in June 2015. PCN members recommend the use of Vedolizumab as a treatment option in line with NICE guidance and a treatment pathway has been developed with local gastroenterologists.
